Functional Dilator Capacity is Independently Associated with Insulin Sensitivity and Age in Central Obesity and is not Improved by High Dose Statin Treatment

Microcirculation

Volumn 18, Issue 1, 2011, Pages 74-84

  Clough, Geraldine F ^a   L'esperance, Veline ^a   Turzyniecka, Magdalena ^a   Walter, Lara ^a   Chipperfield, Andrew J ^b   Gamble, John ^c   Krentz, Andrew J ^a   Byrne, Christopher D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Central obesity; Endothelium; Insulin sensitivity; Laser Doppler fluximetry; Microvasculature; Skin; Statins

Indexed keywords

ATORVASTATIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; HYPEREMIA; HYPERINSULINEMIA; INSULIN SENSITIVITY; LASER DOPPLER FLOWMETRY; MALE; MICROVASCULATURE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ACUTE DISEASE; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD FLOW VELOCITY; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPEREMIA; HYPERINSULINISM; INSULIN RESISTANCE; MALE; MICROCIRCULATION; MIDDLE AGED; OBESITY, ABDOMINAL; PYRROLES; RISK FACTORS; VASODILATION;

EID: 78650538696     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/j.1549-8719.2010.00070.x     Document Type: Article

References (57)

1. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 121(1 Pt 2): 293-298, 1991.
2. Anim-Nyame N, Sooranna SR, Johnson MR, Sullivan MH, Gamble J, Steer PJ. Impaired retrograde transmission of vasodilatory signals via the endothelium in pre-eclampsia: a cause of reduced tissue blood flow? Clin Sci (Lond) 106(1): 19-25, 2004.
3. Avery MR, Voegeli D, Byrne CD, Simpson DM, Clough GF. Age and cigarette smoking are independently associated with the cutaneous vascular response to local warming. Microcirculation 16(8): 725-734, 2009.
4. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52(5): 752-764, 2009.
5. Bollinger A, Yanar A, Hoffman I, Franzeck UK. Is high frequency fluxmotion due to respiration or to vasomotion activity? In: Progress in Applied Microcirculation, edited by Mesmer K Basel: Karger, 1993, pp. 52-55.
6. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJM, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338: b2376, 2009.
7. Caro J, Klittich W, McGuire A, Ford I, Pettitt D, Norrie J, Pettitt D, McMurray J, Shepherd J. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. Eur Heart J 20(4): 263-268, 1999.
8. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, Chiong M, Bustos C, Garcia L, Mellado R, Vukasovic JL, Godoy I, Lavandero S. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant 27(4): 435-441, 2008.
9. Clark MG. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. Am J Physiol Endocrinol Metab 295(4): E732-E750, 2008.
10. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 55(5): 1436-1442, 2006.
11. Clough GF, Chipperfield A, Byrne C, de MF, Gush R. Evaluation of a new high power, wide separation laser Doppler probe: potential measurement of deeper tissue blood flow. Microvasc Res 78(2): 155-161, 2009.
12. Clough GF, Turzyniecka M, Walter L, Krentz AJ, Wild SH, Chipperfield AJ, Gamble J, Byrne CD. Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment. Diabetes 58(5): 1185-1191, 2009.
13. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374): 2005-2016, 2003.
14. Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci 27(9): 503-508, 2006.
15. Czernichow S, Greenfield JR, Galan P, Bastard JP, Charnaux N, Samaras K, Safar ME, Blacher J, Hercberg S, Levy BI. Microvascular dysfunction in healthy insulin-sensitive overweight individuals. J Hypertens 28(2): 325-332, 2010.
16. De Jongh RT, Clark AD, IJzerman RG, Serne EH, de VG, Stehouwer CD. Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 47(6): 978-986, 2004.
17. De Jongh RT, Serne EH, IJzerman RG, de VG, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109(21): 2529-2535, 2004.
18. de Jongh RT, Serne EH, IJzerman RG, Jorstad HT, Stehouwer CD. Impaired local microvascular vasodilatory effects of insulin and reduced skin microvascular vasomotion in obese women. Microvasc Res 75(2): 256-262, 2008.
19. Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med 22(12): 1670-1676, 2005.
20. Frisbee JC, Hollander JM, Brock RW, Yu HG, Boegehold MA. Integration of skeletal muscle resistance arteriolar reactivity for perfusion responses in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 296(6): R1771-R1782, 2009.
21. Gamble J, Christ F, Gartside IB. Human calf precapillary resistance decreases in response to small cumulative increases in venous congestion pressure. Physiol-London 507: 611-617, 1998.
22. Goodwill AG, Frisbee SJ, Stapleton PA, James ME, Frisbee JC. Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Microcirculation 16(8): 667-684, 2009.
23. Granger DN, Rodrigues SF, Yildirim A, Senchenkova EY. Microvascular responses to cardiovascular risk factors. Microcirculation 17(3): 192-205, 2010.
24. Haak E, Abletshauser C, Weber S, Goedicke C, Martin N, Hermanns N, Lackner K, Kusterer K, Usadel KH, Haak T. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 155(2): 395-401, 2001.
25. Hamburg NM, Larson MG, Vita JA, Vasan RS, Keyes MJ, Widlansky ME, Fox CS, Mitchell GF, Levy D, Meigs JB, Benjamin EJ. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 101(1): 82-88, 2008.
26. Hodnett BL, Hester RL. Regulation of muscle blood flow in obesity. Microcirculation 14(4-5): 273-288, 2007.
27. Holowatz LA, Thompson-Torgerson CS, Kenney WL. Altered mechanisms of vasodilation in aged human skin. Exerc Sport Sci Rev 35(3): 119-125, 2007.
28. Kraemer-Aguiar LG, Laflor CM, Bouskela E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism 57(12): 1740-1746, 2008.
29. Kvandal P, Landsverk SA, Bernjak A, Stefanovska A, Kvernmo HD, Kirkeboen KA. Low-frequency oscillations of the laser Doppler perfusion signal in human skin. Microvasc Res 72(3): 120-127, 2006.
30. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
31. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119(1): 131-138, 2009.
32. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolic syndrome. J Hypertens 25(5): 909-920, 2007.
33. McGown CC, Brown NJ, Hellewell PG, Reilly CS, Brookes ZL. Beneficial microvascular and anti-inflammatory effects of pravastatin during sepsis involve nitric oxide synthase III. Br J Anaesth 104(2): 183-190, 2010.
34. Muller-Delp JM. Aging-induced adaptations of microvascular reactivity. Microcirc 13(4): 301-314, 2006.
35. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 28(5): 463-491, 2007.
36. Newman JM, Dwyer RM, St-Pierre P, Richards SM, Clark MG, Rattigan S. Decreased microvascular vasomotion and myogenic response in rat skeletal muscle in association with acute insulin resistance. J Physiol 587(Pt 11): 2579-2588, 2009.
37. Oldfield MA, Brown MD. Evaluation of the time course of vascular responses to venous congestion in the human lower limb. J Vasc Res 43(2): 166-174, 2006.
38. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H; Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 5(3): 81-87, 2004.
39. Prazny M, Kasalova Z, mazoch J, Kvasnicka J, Skrha J. Microvascular reactivity and endothelial function in type 2 diabetic patients with hyperlipidemia treated with simvastatin: 3-year follow-up. Prague Med Rep 110: 290-300, 2009.
40. Robinson JG, Schrott H. Statin pleiotropy: a popular concept but clinical significance unclear. Cardiovasc Drugs Ther 21(2): 81-83, 2007.
41. Rossi M, Carpi A, Di MC, Franzoni F, Galetta F, Santoro G. Skin blood flowmotion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases. Physiol Res 58(1): 39-47, 2009.
42. Roustit M, Blaise S, Millet C, Cracowski JL. Reproducibility and methodological issues of skin post-occlusive and thermal hyperemia assessed by single-point laser Doppler flowmetry. Microvasc Res 79(2): 102-108, 2010.
43. Schmiedel O, Schroeter ML, Harvey JN. Microalbuminuria in Type 2 diabetes indicates impaired microvascular vasomotion and perfusion. Am J Physiol Heart Circ Physiol 293(6): H3424-H3431, 2007.
44. Soderstrom T, Stefanovska A, Veber M, Svensson H. Involvement of sympathetic nerve activity in skin blood flow oscillations in humans. Am J Physiol Heart Circ Physiol 284(5): H1638-H1646, 2003.
45. Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology 15(2): 79-89, 2008.
46. Stauss HM, Anderson EA, Haynes WG, Kregel KC. Frequency response characteristics of sympathetically mediated vasomotor waves in humans. Am J Physiol 274(4 Pt 2): H1277-H1283, 1998.
47. Stefanovska A, Bracic M, Kvernmo HD. Wavelet analysis of oscillations in the peripheral blood circulation measured by laser Doppler technique. IEEE Trans Biomed Eng 46(10): 1230-1239, 1999.
48. Stewart JM, Taneja I, Goligorsky MS, Medow MS. Noninvasive measure of microvascular nitric oxide function in humans using very low-frequency cutaneous laser Doppler flow spectra. Microcirculation 14(3): 169-180, 2007.
49. Strain WD, Chaturvedi N, Bulpitt CJ, Rajkumar C, Shore AC. Albumin excretion rate and cardiovascular risk: could the association be explained by early microvascular dysfunction? Diabetes 54(6): 1816-1822, 2005.
50. Stulc T, Kasalova Z, Prazny M, Vrablik M, Skrha J, Ceska R. Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. Physiol Rev 52: 439-445, 2003.
51. Torrens C, Kelsall CJ, Hopkins LA, Anthony FW, Curzen NP, Hanson MA. Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner. Hypertension 53(4): 661-667, 2009.
52. Turzyniecka M, Wild SH, Krentz AJ, Chipperfield AJ, Gamble J, Clough GF, Byrne CD. Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in subjects with central obesity. Diabet Med 26(11): 1112-1119, 2009.
53. Virdis A, Colucci R, Versari D, Ghisu N, Fornai M, Antonioli L, Duranti E, Daghini E, Giannarelli C, Blandizzi C, Taddei S, Del Tacca M. Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 53(6): 1008-1016, 2009.
54. Wilhelmsen L, Pyorala K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 22(13): 1119-1127, 2001.
55. Xiang L, Dearman J, Abram SR, Carter C, Hester RL. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am J Physiol Heart Circ Physiol 294(4): H1658-H1666, 2008.
56. Yamamoto-Suganuma R, Aso Y. Relationship between post-occlusive forearm skin reactive hyperaemia and vascular disease in patients with Type 2 diabetes--a novel index for detecting micro- and macrovascular dysfunction using laser Doppler flowmetry. Diabet Med 26(1): 83-88, 2009.
57. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12(6): 295-300, 2005.